Bioline RX Ltd (NASDAQ:BLRX) announced that detailed results from a study on the underlying mechanism of action of BL-8040, its lead platform for the …
Bioline RX Ltd (NASDAQ:BLRX) announced that its partner, Omega Pharma, now part of Perrigo, has received CE Mark approval for BL-5010 as a novel …
Bioline RX Ltd (NASDAQ:BLRX) announced positive top-line results from BL-8040’s Phase 2 clinical trial in relapsed or refractory acute myeloid leukemia (r/r AML). Detailed …
Bioline RX Ltd (NASDAQ:BLRX) announced the initiation of a Phase 2 trial for BL-8040 as a novel approach for the mobilization and collection of …
Bioline RX Ltd (NASDAQ:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the …
Bioline RX Ltd (NASDAQ:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced that it has received confirmation from …
Bioline RX Ltd (NASDAQ: BLRX) announced a collaboration with MSD, known as Merck in the US and Canada, to support a Phase 2 study …
Bioline RX Ltd (NASDAQ:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the filing of regulatory submissions …
Bioline RX Ltd (NASDAQ:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported the establishment of a Scientific …
Bioline RX Ltd (NASDAQ:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has commenced a …
